Epilepsy is a group of neurological disorders characterized by brief, involuntary episodes of vigorous shaking of a part or complete body. The patient may experience loss or disturbance of consciousness and movements along with sensory or psychiatric disturbances. About 24 million people around the globe had epilepsy in 2015 across the globe. Grand mal seizures or tonic–clonic seizures are a type of generalized seizures, which affect the entire brain and are the most common type of epileptic seizures. Grand mal seizures are caused by neurotransmitter imbalances, which can also be influenced by fatigue, lack of sleep, hypertension, stress, intense lighting, rapid motion, blood sugar level, anxiety, etc. The grand mal seizures consist of two phases, the tonic phase and the clonic phase. The tonic phase involves loss of consciousness and muscle twitching and the phase usually last only for a few seconds. The clonic phase consists of rapid muscle contraction and relaxation resulting in convulsions.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4087
Development of better tolerated third generation drugs, increasing screening of patients, and growing geriatric population- they are more susceptible to epilepsy- drive the growth of the market. Increased patent expiry for a number of anti-epilepsy drugs such as Neurontin (2003) and Lyrica (scheduled in 2018), unknown origin and action mechanism of epilepsy, and concurrent lack of innovative drugs are likely to affect the market growth negatively. The market is also constrained by the poor efficacy and efficiency of most of the anti-epileptic drugs. A sizeable segment of patients respond very poorly or none at all to main line drugs such as the Gamma Aminobutyric Acid Modulators and ion channel blockers. These drugs have serious adverse effect on the patient such as depression, and suicidal behaviour, dizziness, fatigue, weight gain, etc. Social stigma associated with the epilepsy, especially, in the developing countries may hamper the market over the forecast period.
The global grand mal seizures market is expected to reach US$ 2.8 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.2 % during the forecast period 2017-2023.
The global grand mal seizure market has been segmented on the basis of drug generation, drug class, surgery, diagnosis, and end users. Based on drug generation, the market has been segmented as the first generation, the second generation, and the third generation. Based on the drug class, the market has been segmented as barbiturates, hydantoin, cyclic gaba analogues, phenyltriazine, iminostilbenes, aliphatic carboxylic acid, benzodiazepines, and others. Based on the surgery, the market has been segmented as resective surgery, multiple subpial transection, hemispherectomy, corpus callosotomy, and others. Based on the diagnosis, the market has been segmented as electroencephalogram (EEG), magnetic resonance imaging (MRI), computed tomography (CT), blood tests, and others. Based on the end users, the market has been segmented as hospitals, neurological centers, academic and research center, and others.
The Americas accounts for the significant market share owing to extensive use of medications and greater expenditure on the health care. Additionally, the fastest uptake of new technology and drugs in the US drives the global grand mal seizures market. The concentration of the major medical diagnostic device manufacturers in the developed regions is also adding fuel to the market. Europe is the second largest market due to a high disposable income and rising awareness about the grand mal seizures.
Asia Pacific region is expected to grow rapidly and China and India are likely to lead the market during the forecast period.
Gulf nations, Saudi Arabia and the UAE, drive the Middle East & African market. The African region is expected to witness a moderate growth owing to poor economic and political conditions and poor healthcare development.
Key Players in the Global Grand Mal Seizure Market
Some of key players profiled in the report are Pfizer, Inc., Johnson & Johnson Services, Inc., UCB Celltech, Abbott Laboratories, GlaxoSmithKline plc, Novartis AG, Sanofi. Shire Pharmaceuticals Limited, and Teva Pharmaceutical Industries.
The report for Global Grand mal seizure market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/grand-mal-seizure-market-4087